Correlation Between Entrada Therapeutics and 50249AAJ2

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Entrada Therapeutics and 50249AAJ2 at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entrada Therapeutics and 50249AAJ2 into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Entrada Therapeutics and LYB INTERNATIONAL FINANCE, you can compare the effects of market volatilities on Entrada Therapeutics and 50249AAJ2 and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entrada Therapeutics with a short position of 50249AAJ2. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entrada Therapeutics and 50249AAJ2.

Diversification Opportunities for Entrada Therapeutics and 50249AAJ2

-0.51
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Entrada and 50249AAJ2 is -0.51. Overlapping area represents the amount of risk that can be diversified away by holding Entrada Therapeutics and LYB INTERNATIONAL FINANCE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on LYB INTERNATIONAL FINANCE and Entrada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entrada Therapeutics are associated (or correlated) with 50249AAJ2. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of LYB INTERNATIONAL FINANCE has no effect on the direction of Entrada Therapeutics i.e., Entrada Therapeutics and 50249AAJ2 go up and down completely randomly.

Pair Corralation between Entrada Therapeutics and 50249AAJ2

Given the investment horizon of 90 days Entrada Therapeutics is expected to under-perform the 50249AAJ2. In addition to that, Entrada Therapeutics is 2.49 times more volatile than LYB INTERNATIONAL FINANCE. It trades about -0.07 of its total potential returns per unit of risk. LYB INTERNATIONAL FINANCE is currently generating about -0.09 per unit of volatility. If you would invest  6,945  in LYB INTERNATIONAL FINANCE on September 23, 2024 and sell it today you would lose (203.00) from holding LYB INTERNATIONAL FINANCE or give up 2.92% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Entrada Therapeutics  vs.  LYB INTERNATIONAL FINANCE

 Performance 
       Timeline  
Entrada Therapeutics 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Entrada Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.
LYB INTERNATIONAL FINANCE 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days LYB INTERNATIONAL FINANCE has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Bond's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for LYB INTERNATIONAL FINANCE investors.

Entrada Therapeutics and 50249AAJ2 Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Entrada Therapeutics and 50249AAJ2

The main advantage of trading using opposite Entrada Therapeutics and 50249AAJ2 positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entrada Therapeutics position performs unexpectedly, 50249AAJ2 can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in 50249AAJ2 will offset losses from the drop in 50249AAJ2's long position.
The idea behind Entrada Therapeutics and LYB INTERNATIONAL FINANCE pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules